in deeper plaque areas, atherosclerotic lesions harbor areas of hypoxia, 11 and HIF-1α can be detected in atherosclerotic lesions in both mice and humans. [11] [12] [13] [14] The direct cell-specific role of HIF1α in atherosclerosis in vivo, however, has not been addressed previously.
We here investigated the function of HIF1α in atherosclerosis in antigen-presenting cells (APCs). By deleting Hif1a specifically in CD11c + cells, we here reveal a critical role of HIF1α in balancing APC-driven Th1 polarization during atherogenesis in LDL receptor-deficient (Ldlr −/− ) mice and to attenuate the progression of atherosclerosis in Ldlr −/− mice.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

HIF1α Expression in Atherosclerosis
Hypoxic areas, as well as Hif1a expression, have previously been demonstrated in human and murine atherosclerotic lesions. 11, 14 Consistent with this, we detected hypoxic regions in atherosclerotic plaques in aortic roots of Ldlr −/− mice fed a high-fat diet for 8 weeks ( Figure 1A ) but not in healthy 6-week-old Ldlr −/− mice on normal chow by hypoxyprobe staining (not shown); no staining was seen in Ldlr −/− mice without hypoxyprobe performed as a negative control ( Figure  1A ). Likewise, Hif1a mRNA and protein expressions were significantly upregulated in aortae of atherosclerotic Ldlr Figure 1D ), and the majority of CD11c + cells showed colocalization with HIF1α ( Figure 1D ), indicating HIF1α expression in lesional APCs. Moreover, increased expression of Hif1α mRNA was observed in splenic APCs from atherosclerotic Ldlr −/− mice ( Figure 1E ), indicating systemic upregulation of HIF1α in addition to localized effects in aortic lesions.
Targeted Deletion of Hif1a in CD11c + APCs Accelerates Atherosclerotic Lesion Formation
To address the function of HIF1α in APCs, mice with a CD11c-specific deletion of Hif1a were generated, as ) APCs. In CD4 + T cells, only a marginal reduction was observed (≈5%; Figure IA in the online-only Data Supplement). Likewise, Hif1a mRNA expression was reduced in isolated Hif1a-CKO Ldlr −/− APCs and Hif1a-CKO bone marrow-derived DCs (BMDCs) 15 when compared with controls ( Figure IB and IC in the online-only Data Supplement).
To study atherosclerotic lesion formation, 15 Hif1a-WT Ldlr −/− and Hif1a-CKO Ldlr −/− mice were placed on a high-fat diet for 8 weeks. Body weight (28.9±0.7 versus 30.3±1.3 g), serum total cholesterol (12.7±1.0 versus 12.9±1.8×1000 μg/ mL), and triglyceride levels (6.1±0.2 versus 5.6±0.1 mmol/L) did not differ between Hif1a-WT Ldlr −/− and Hif1a-CKO Ldlr −/− mice. We observed a 2.3-fold increase in atherosclerotic plaque growth in the aortic root and a 1.6-fold increase in the aorta of Hif1a-CKO Ldlr −/− when compared with that of Hif1a-WT Ldlr −/− mice ( Figure 2A and 2B). Plaque cell density was unaltered between groups (4420±241. 6 Figure 2F ), indicating that an enhanced accumulation of T cells within lesions was associated with an accelerated plaque growth because of deficiency of HIF1α in APCs.
HIF1a-Deficient APCs Promote T-Cell Activation and Th1 Polarization in Atherosclerosis
T-cell activation and differentiation are governed by APCs and drive atherosclerotic lesion development. 4, 6, 15 Hif1a-CKO versus Hif1a-WT mice on normal chow ( Figure  III in the online-only Data Supplement). These data suggest that HIF1α activation in APCs plays a crucial role in restraining T-cell activation and Th1 cell differentiation under inflammatory conditions in atherosclerosis, while being dispensable under homeostatic conditions. Notably, an increased percentage of IFN-γ + CD4 + T cells was also evidenced in LNs and spleens of Hif1a-CKO when compared with those of Hif1a-WT mice after immunization with ovalbumin (OVA) protein as an artificial model antigen ( Figure IV in the online-only Data Supplement), corroborating an important role of HIF1α in controlling APC-driven Th1 T-cell polarization also under systemic inflammatory conditions unrelated to atherosclerosis.
Macrophages and DCs share phenotypic features. 16 In particular, CD11c is expressed by both DCs and some macrophage subsets. To gain insight into the potential role of HIF1α in macrophages versus DCs among total APCs, atherosclerotic lesion formation was also assessed in Ldlr −/− mice reconstituted with BM of LysM-cre + Hif1a flox/flox mice. 17 Efficient deletion of Hif1a mRNA expression (≈70%-80%) was confirmed in BM-derived LysM-cre + Hif1a flox/flox macrophages under normoxic and hypoxic conditions ( Figure VA in the online-only Data Supplement). After 6 weeks of high-fat diet, no differences in serum cholesterol, plaque size, and cellular plaque composition were noted. Moreover, no alterations in T-cell distributions and activation were observed in spleens or LNs (Figure VB and VC and Furthermore, an alternative approach supports the importance of HIF1α in immune stimulating APCs, as untreated and tumor necrosis factor-α-stimulated BM-derived macrophages 18 from Hif1a-CKO and Hif1a-WT mice did not display any consistent differences in proinflammatory Il12, Nos2, or anti-inflammatory Mrc1 and Igf1 mRNA expression ( Figure  VD in the online-only Data Supplement).
HIF1α Controls Inflammatory IL-12 Expression in APCs by Regulating Signal Transducers and Activators of Transcription 3 Expression
The migration of APCs is essential for efficient T-cell activation and controlled by CCR7. 19 However, unchanged Ccr7 expression in Hif1a-KO BMDCs or APCs from atherosclerotic Hif1a-CKO Ldlr −/− mice and BMDC migration toward CCL19 (Figure VIA-VIC in the online-only Data Supplement) point toward effects of HIF1α unrelated to CCR7-driven APC migration.
T-cell activation and Th cell polarization are shaped by costimulatory molecule engagement and exposure to a specific cytokine milieu, with Th1 cells critically depending on IL-12 secretion from DCs. 20, 21 No significant changes in mRNA or surface protein expression of MHC-II, CD80, and CD86 were noted in tumor necrosis factor-α matured Hif1a-CKO versus HIF1α has been shown to induce and to synergistically act with nuclear factor-κB. 10 However, Nfkb1/p105 and Rela/ p65 transcript or protein expression ( Figure IXA in the onlineonly Data Supplement, and data not shown) were similar in mature Hif1a-WT versus Hif1a-CKO BMDC.
STAT3 has been shown to inhibit IL-12 cytokine production in DCs. 22, 23 Notably, a significant reduction in Stat3 mRNA and protein expression could be detected in mature 
HIF1α Controls Inflammatory T-Cell Responses in Atherosclerosis
Importantly, HIF1α also functions to promote STAT3 expression in APCs in atherosclerosis in vivo, as witnessed by a significant reduction in both Stat3 transcript and protein levels in splenic APCs from atherosclerotic Hif1a-CKO Ldlr 
HIF1α-Deficient APCs Promote Atherosclerosis Because Of Reduced STAT3 Expression
To further confirm that Hif1a-CKO APCs promote atherosclerosis in a STAT3-dependent manner, we used a Cre-dependent system for STAT3 expression (pLB2-Ubi-FLIP Figure 5A-5C ). Moreover, this was paralleled by a reduction of the elevated total numbers of T cells in the aorta, and an abrogation of increased frequencies of IFN-γ + CD4 + T cells in spleens of these mice ( Figure 5D and 5E), clearly indicating that diminished STAT3 entails proatherogenic effects of Hif1α deficiency in APCs. WT-BM+Stat3-virus→Ldlr −/− mice displayed a reduction in atherosclerotic lesion formation in the aortic root but not in the aorta, no changes in aortic T-cell frequencies and a small trend toward decreased Th1 cell responses in the spleen when compared with WT-BM+Ctrl-virus→Ldlr −/− mice ( Figure 5A and 5B), suggesting that prevailing actions of natural HIFα on STAT3 expression in WT APCs dampen effects of an additional overexpression in atherosclerosis. Splenic APC isolated from WT-BM+STAT3- 
Expression of HIF1α, STAT3, and IL-12 in APCs in Human Atherosclerotic Lesions
To finally assess whether these mechanisms may also be relevant to human disease, immunostaining of human atherosclerotic carotid artery plaques was performed. Similar to findings in mice and previous reports, [11] [12] [13] [14] we detected hypoxia and abundant HIF1α protein expression in atherosclerotic carotid artery plaque tissue ( Figure 6A ). Costaining for the APC markers S100 or CD11c revealed that the majority of APCs were hypoxic and expressed HIF1α, respectively ( Figure 6A-6C) . Furthermore, we could detect both STAT3 and IL-12 protein in colocalization with S100 + APCs ( Figure  6A ). These data indicate that APCs express HIF1α, STAT3, and IL-12 in human atherosclerotic lesions. In addition, realtime-polymerase chain reaction analyses of atherosclerotic plaques obtained from patients with high-grade carotid artery stenosis, histologically classified as early and advanced stages of atherosclerosis, demonstrated increased HIF-1α and STAT3 mRNA expression, but decreased IL12 transcript expression in advanced compared with early lesions ( Figure 6D ).
Discussion
Although T-cell responses and, in particular, Th1-mediated immunity drive atherosclerotic lesion formation, 8 the pathways in APCs that control T-cell activation remain largely elusive. The transcription factor HIF1α is known to modulate immune responses 10 and to be found in atherosclerotic plaques.
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We here unveil that HIF-1α expression is upregulated in CD11c + APCs in atherosclerotic Ldlr −/− mice. To assess the (patho-) physiological relevance of HIF-1α in this cell type, we used CKO mice with a deletion of Hif1a in CD11c + APCs in Ldlr −/− mice. Importantly, an accelerated atherosclerotic lesion formation was observed in mice deficient in HIF-1α in APCs, together with an expansion of proinflammatory Th1 cells both locally within lesions and systemically, indicating that APC-expressed HIF-1α is of paramount importance in balancing uncontrolled Th1-cell responses and atherosclerosis in Ldlr −/− mice. Mechanistically, we could demonstrate that HIF1α directly binds the Stat3 promoter to control its transcription. Overexpression of Stat3 in Hif1a-deficient APCs in BM reversed enhanced atherosclerotic lesion formation and reduced Th1-cell expansion in chimeric Ldlr −/− mice. These findings offer unique insight into the regulatory function of HIF1α in APCs ( Figure XI in the online-only Data Supplement), and substantiate the critical role of APCs in controlling immune mechanisms that drive atherogenesis.
In humans and apolipoprotein E-deficient mice, HIF1α expression was detected in atherosclerotic lesions and to increase from early to stable lesions. 11, 13, 14 In line, we were able to detect an upregulation of HIF1α expression in atherosclerotic aortae and aortic roots of Ldlr −/− mice when compared with healthy controls, and in advanced versus early human atherosclerotic lesions. Expressed in many cell types, HIF1α was also found to colocalize with hypoxic CD11c + cells within lesions in both mice and humans.
Limited evidence on the role of HIF1α in atherosclerotic lesion formation exists. Mice lacking HIF1α in CD4 + T cells were previously shown to display increased T-cell activation, associated with an augmented neointimal femoral artery hyperplasia after cuff placement. 28 Systemic hydrodynamic injection of plasmids encoding constitutively active Hif1a into Apoe −/− mice, resulting in HIF1α overexpression predominantly in CD4 + T cells, lead to a reduction in lesion formation, associated with a shift toward an anti-inflammatory cytokine expression profile in CD4 + T cells. 29 However, in contrast to these studies, which would be consistent with an induction of Foxp3 and regulatory T cells by HIF1α 30 and the demonstration of a protective function of regulatory T cells in atherosclerosis, 8 deficiency in HIF1α was more recently shown to diminish Th17 but to enhance regulatory T-cell development in CD4 + T cells. 31 In macrophages, HIF1α has been described to be critical for maintaining intracellular energy homeostasis, and Hif1a-deficient LysM-cre + macrophages were shown to display normal cytokine production but an abrogated migratory capacity, preventing skin infiltration and inflammation. 17 However, a reduced production of proinflammatory cytokines was demonstrated in Hif1a-deficient LysM-cre + macrophages in response to lipopolysaccharide, together with a protection from lipopolysaccharide-induced sepsis. 32 In the context of atherosclerosis, HIF1α was suggested to exert proatherogenic functions in cultured macrophages by promoting cholesterol accumulation.
14 Variable effects of hypoxia-induced HIF1α expression have also been shown in DCs. For instance, a reduction in costimulatory molecule expression and of the stimulatory capacity for T-cell functions was observed in 1 study, whereas increased expression of costimulatory molecules and an induction of allogeneic lymphocyte proliferation in response to lipopolysaccharide was noted in an another report in vitro, whereas both studies described an upregulated production of proinflammatory cytokines. 33, 34 Before our study, the direct in vivo role of HIF1α in APCs in atherosclerosis had not been addressed.
We here deleted Hif1a specifically in CD11c + APCs, allowing a definite assessment of its role under physiological conditions and in atherosclerosis in vivo. APCs differentiated normally with no differences in their numbers or maturation in Hif1a-deficient mice. Moreover, no differences in APC phenotype and T-cell activation were noted in young, healthy mice, indicating that HIF1α plays a subordinate role in maintaining homeostatic APC functions. In atherosclerotic Ldlr −/− mice, however, a significant increase in IL-12 was observed in Hif1a-deficient APCs, whereas other cytokines and the expression of MHC-II and costimulatory molecules were unaltered. Moreover, an enhanced activation of CD4 + T cells and increased frequencies of Th1 cells were observed in Hif1a-CKO Ldlr −/− versus Hif1a-WT Ldlr −/− mice in vivo in the aorta and spleen, and in cocultures with Hif1a-deficient APCs isolated from atherosclerotic Ldlr −/− mice and loaded with OVA as a model antigen in vitro. These data suggest that Hif1a deficiency in APCs drives T-cell activation and Th1 differentiation, and that the effects of HIF1α deficiency are systemic.
Hypoxia can frequently be detected in atherosclerotic plaques. Hypoxyprobe (pimonidazole) is metabolized in living cells experiencing oxygen levels below 10 mm Hg (≈1% O 2 ). Cells positive for pimonidazole are thus viable and hypoxic, but do not experience a total lack of oxygen (anoxia). Both the thickness of the plaque exceeding the maximum oxygen diffusion distance, and more importantly, the high metabolic demand of cells within chronically inflamed tissue contribute to plaque hypoxia also within the oxygen diffusion limit in symptomatic patients, rabbits, and mice. 11, 12, 35 In line, we detected hypoxic regions in atherosclerotic lesions of Ldlr −/− mice in luminal and intramural plaque cells. In addition to hypoxia, however, HIF1α expression can also be triggered and potentiated by oxidized LDL, lipopolysaccharides, and proinflammatory cytokines. 9, 36, 37 Hence, HIF1α expression in hypoxic vascular APCs, known to ingest lipids and to be exposed to cytokines, 4 may arise from a combination of these factors. Likewise, increased HIF1α in splenic APCs may have been activated by systemically increased lipid mediators or atherogenic cytokines, possibly in combination with relative hypoxia because of higher oxygen consumption under conditions of splenic inflammation. In this regard, it is interesting that similar changes in Th1 polarization were observed on systemic immunization with OVA in otherwise healthy CKO mice, providing further evidence that HIF1α controls APC-driven T-cell responses in inflammation also unrelated to atherosclerosis.
Increased atherosclerotic lesion size in Hif1a-CKO Ldlr −/− mice was accompanied by an increased necrotic core area. It was recently shown that silencing of HIF1α provokes a loss in viability with increased rates of apoptosis and necrosis in cultured human macrophages, potentiated in the presence of oxidized LDL or under hypoxic conditions. 38 Although the potential impact of reduced monocyte/macrophage viability in atherosclerotic plaques is unclear and may depend on plaque stage, an increased apoptosis/necrosis of HIF1α-deficient APCs may have contributed to the expansion of the necrotic core in our model, warranting further investigations of this mechanism and its impact on atherogenesis in the future.
Notably We did not detect any alterations in nuclear factor-κB, IκB Kinase α, or inhibitor of nuclear factor κB α (IκBα) expression in APCs deficient in HIF1α, similar to Hif1α-deficient LysM-cre + macrophages, 32 indicating that the deletion of Hif1a does not directly affect the nuclear factor-κB pathway per se. In agreement with the identification of binding sites in silico, ChIP analyses demonstrated direct binding of HIF1α to the Stat3 promoter, and Hif1a-deficient APCs to display a reduction in Stat3 mRNA and protein expression. These findings reveal HIF1α as an important regulator of STAT3 expression. Interestingly, STAT3 is known to exert immune-suppressive and anti-inflammatory functions in myeloid cells, 41 and mice with Stat3-deficient APCs were previously shown to produce significantly more IL-12 in response to lipopolysaccharide, associated with an increased capacity to stimulate T-cell proliferation and IFN-γ secretion. 22 Accordingly, overexpression of STAT3 reduced Il12 transcript levels in BMDCs, whereas a dominant negative mutant of STAT3 elevated Il12 expression, corroborating evidence that STAT3 interferes with Il12 transcription. 22, 42 Importantly, these effects occurred down-stream of HIF1α, as also evidenced in Hif1a-deficient APCs. Lentiviral transduction of Hif1a-CKO BM with overexpression of STAT3 in APCs reversed the enhanced atherosclerotic lesion formation, decreased T-cell infiltrates, and reduced Th1-cell polarization in chimeric Ldlr −/− mice, confirming that increased levels of HIF1α and STAT3 in APCs are pivotal in controlling atherosclerotic plaque formation. In line with a clear but nonsignificant trend toward increased STAT3 expression in splenic APCs, marginal effects on plaque size and unaffected aortic T-cell accumulation and Th1 cell responses were observed in WT-BM+Ctrl-virus→Ldlr −/− versus WT-BM+STAT3-virus→Ldlr −/− mice. This may indicate that reduced STAT3 availability in CKO APCs rather than its additional supplementation in WT APCs that already inherently display increased HIF1α and STAT3 levels in atherosclerosis determines disease development in this setting.
Interestingly, human APCs exposed to hypoxia that display increased levels of HIF1α showed a reduced secretion of IL-12 43 and induced lower T-cell IFN-γ production, 34, 43 suggesting an HIF1α-triggered pathway restraining Th1 responses in human APCs. Notably, extending previous findings describing the presence of hypoxia and HIF1α in human atherosclerotic lesions, [11] [12] [13] [14] we here demonstrate that APCs express HIF1α, STAT3, and IL-12 in human atherosclerotic lesions. Furthermore, an increased HIF1α and STAT3 but a decreased IL-12 mRNA expression was observed in advanced versus early carotid artery plaques. These data suggest that the regulatory signaling axis revealed in our study in APCs in mice may also be operative in human disease. Interestingly, IL-12 expression in plasma and plaque tissue was previously shown to correlate with IFN-γ expression, with T cells being the principal source of IFN-γ in the arterial wall in humans, 44 in line with the notion that IL-12-controlled Th1 T-cell responses are of primary importance during plaque development.
The bidirectional effects of HIF1α-deficiency in APCs on other lesional cell types and their contribution to lesion formation remain to be addressed. For instance, mast cells are present in atherosclerotic plaques and are considered to promote lesion growth and plaque destabilization. 45 Mast cellderived cytokines, via an induction of HIF1α in APCs, may have led to an attenuated proatherogenic APC phenotype balancing overshooting inflammation in atherosclerosis, and be in line with mast cells often ensuing Th2-type inflammatory responses. 45, 46 However, proinflammatory mediators released by mast cells, as induced by the contact with T cells, which showed an increased activation in CKO Ldlr −/− mice, may have also contributed to enhanced inflammation 45, 46 and plaque progression in our study.
Although it is widely acknowledged that Th1-mediated immune responses drive atherosclerotic lesion formation, 6 still little is known about the pathways and transcription factors in APCs that drive T-cell polarization in atherosclerosis. Moreover, although HIF-1α can be detected in atherosclerotic lesions in both mice and humans [11] [12] [13] [14] and can modulate immune responses, 10 its cell-specific role in atherosclerosis had not been addressed previously. Our findings demonstrate that HIF1α balances APC activation and Th1 polarization during atherogenesis in Ldlr −/− mice and attenuates disease progression.
